HANSOH PHARMA (03692.HK): Small Cell Lung Cancer Product HS-20093 Included in NMPA Priority Review Procedure
NewTimeSpace News: On 11 September 2026, Hansoh Pharmaceutical Group Company Limited (stock code: 03692.HK) announced that, based on positive results from the pivotal Phase III trial ARTEMIS-008, Ruikang Lifutuota Monoclonal Antibody for injection (HS-20093) has been included in the priority review and approval procedure of China's National Medical Products Administration (NMPA) for the indication of small cell lung cancer that has failed platinum-containing treatment on 21 August 2026.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HANSOH PHARMA (03692.HK): Refiles EU Marketing Application for Aumseqa
- Hansoh(03692.HK): EU revokes Aumolertinib approval, EMA resubmission planned
- HANSOH PHARMA (03692.HK): NMPA Accepts NDA for HS-20093, Its B7-H3-Targeting ADC, in Osteosarcoma
- HANSOH PHARMA (03692.HK): HS-20093 Gets Osteosarcoma Priority Review
- HANSOH PHARMA (03692.HK): HS-10374 meets co-primary endpoints in Phase III psoriasis trial
